Literature DB >> 17127196

Infection and musculoskeletal conditions: Prosthetic-joint-associated infections.

Werner Zimmerli1.   

Abstract

In patients with osteoarthritis or arthritis, prosthetic joint replacement is increasingly used to alleviate pain and to improve mobility. The most important risk factors are comorbidity and prior joint replacement (revision surgery). Diagnosis of prosthetic-joint-associated infection is difficult, because the infecting agent may be missed in synovial fluid due to its exclusive presence as a device-associated biofilm. Implant-associated infections are difficult to treat because of their resistance to natural host defence mechanisms and to most antibiotics. In staphylococcal implant-associated infections a rifampin combination should be used, because this drug has an excellent efficacy on surface-adhering microorganisms. Antimicrobial therapy must always be combined with the correct surgical treatment which is chosen according to an algorithm. The use of antibiotics during procedures with potential bacteraemia is controversial because evidence for its need is lacking. In contrast, during sepsis rapid antibiotic therapy is needed to prevent haematogenous seeding on the artificial joint.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127196     DOI: 10.1016/j.berh.2006.08.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  57 in total

1.  Outcomes of revision total knee arthroplasty after methicillin-resistant Staphylococcus aureus infection.

Authors:  Dann J Laudermilch; Catherine J Fedorka; Alma Heyl; Nalini Rao; Richard L McGough
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

2.  Bacterial colonization of bone allografts: establishment and effects of antibiotics.

Authors:  Constantinos Ketonis; Stephanie Barr; Christopher S Adams; Noreen J Hickok; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

Review 3.  Laboratory diagnosis of Prosthetic Joint Infections: Current concepts and present status.

Authors:  Raju Vaishya; Raman Sardana; Hena Butta; Leena Mendiratta
Journal:  J Clin Orthop Trauma       Date:  2018-10-16

4.  Evaluation of quantitative analysis of cultures from sonicated retrieved orthopedic implants in diagnosis of orthopedic infection.

Authors:  Jaime Esteban; Enrique Gomez-Barrena; Jose Cordero; Nieves Zamora Martín-de-Hijas; Teemu J Kinnari; Ricardo Fernandez-Roblas
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

5.  Prosthetic Joint Infections in Patients Undergoing Carpal Tunnel Release.

Authors:  Wenjing Zeng; Deborah Paul; Thomas Kemp; John Elfar
Journal:  J Am Acad Orthop Surg       Date:  2017-03       Impact factor: 3.020

Review 6.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

7.  Periprosthetic joint infections: a clinical practice algorithm.

Authors:  Luigi Volpe; Pier Francesco Indelli; Leonardo Latella; Paolo Poli; Jale Yakupoglu; Massimiliano Marcucci
Journal:  Joints       Date:  2015-02-13

8.  The Artelon CMC spacer compared with tendon interposition arthroplasty.

Authors:  Anders Nilsson; Monica Wiig; Håkan Alnehill; Magnus Berggren; Sten Björnum; Mats Geijer; Philippe Kopylov; Christer Sollerman
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

9.  Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis.

Authors:  Cody Fisher; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 10.  Revision of late periprosthetic infections of total hip endoprostheses: pros and cons of different concepts.

Authors:  Bernd Fink
Journal:  Int J Med Sci       Date:  2009-09-04       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.